Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Deferred Taxes (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Deferred Taxes for 5 consecutive years, with -$71000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Deferred Taxes fell 2266.67% year-over-year to -$71000.0, compared with a TTM value of -$115000.0 through Sep 2025, up 86.75%, and an annual FY2024 reading of -$44000.0, up 98.57% over the prior year.
  • Deferred Taxes was -$71000.0 for Q3 2025 at Barinthus Biotherapeutics, down from -$25000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $3000.0 in Q4 2024 and bottomed at -$1.9 million in Q4 2022.
  • Average Deferred Taxes over 5 years is -$404894.7, with a median of -$57000.0 recorded in 2021.
  • The sharpest move saw Deferred Taxes crashed 12971.43% in 2022, then surged 100.37% in 2024.
  • Year by year, Deferred Taxes stood at -$57000.0 in 2021, then tumbled by 3292.98% to -$1.9 million in 2022, then surged by 57.55% to -$821000.0 in 2023, then soared by 100.37% to $3000.0 in 2024, then tumbled by 2466.67% to -$71000.0 in 2025.
  • Business Quant data shows Deferred Taxes for BRNS at -$71000.0 in Q3 2025, -$25000.0 in Q2 2025, and -$22000.0 in Q1 2025.